new glp-1 weight loss Professor Receives Grant to Study Effectiveness of Weight-Loss Drugs Most Patients Keep Weight Off

Lean mass loss with GLP-1 medicines is generally proportional to total weight lost, about 25 to 30 percent, similar to other weight-loss interventions, and physical function and quality of life improve

Compounded semaglutide injections prepared by licensed 503A pharmacies must be used within 28 days of reconstitutiona requirement rooted in pharmaceutical stability testing and patient safety

GLP-1RAs inhibit RGC apoptosis in glaucoma through GABAergic signaling, but their role in AMD, characterized by oxidative stress and choroidal neovascularization, needs further investigation (Shao et al., 2024)

Future research will focus on the benefit of tirzepatide in patients with chronic kidney disease and non-alcoholic fatty liver disease